Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

Casdatifan plus Cabometyx showed promising activity and tolerability in clear cell renal cell carcinoma patients in the ARC-20 trial. Welireg dosing regimens demonstrated varying response rates, with ...

In May 2025, Merck announced that the FDA approved WELIREG , the company's oral inhibitor of hypoxia-inducible factor-2 alpha (HIF-2α), for treating adults and children aged 12 and older with ...

WELIREG's prescribing information includes a boxed warning noting that exposure during pregnancy may cause harm to the fetus.

The FDA has approved Welireg (belzutifan) for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic PPGL.

WELIREG becomes the only approved and available treatment in the U.S. for eligible patients with advanced PPGL RAHWAY, N.J. -- (BUSINESS WIRE)-- Merck (MRK), known as MSD outside of the United ...

WELIREG can cause fetal harm when administered to a pregnant woman. Verify the pregnancy status of females of reproductive potential prior to initiating treatment with WELIREG.

Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has conditionally approved Welireg (belzutifan), Merck’s oral hypoxia-inducible factor-2 alpha ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has conditionally approved WELIREG® (belzutifan), Merck’s oral ...

Merck & Co’s – known as MSD outside of the US and Canada – Welireg (belzutifan) has been conditionally approved by the European Commission (EC) as a monotherapy for certain patients with von ...

WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union ...